Drug intelligence / Profile preview

BTX-401

Development stage: Preclinical
Lead developer: Human Stem Cells Institute
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BTX-401 is a recombinant protein vaccine candidate developed by the Human Stem Cells Institute (Artgen) and its subsidiary Betuvax for the prevention of Human Papillomavirus (HPV) infection. The vaccine is built on the 'Betusfera' platform, which utilizes a corpuscular adjuvant derived from betulin, a natural triterpenoid found in birch bark. This platform is designed to enhance the immunogenicity of recombinant proteins while maintaining a high safety profile. BTX-401 aims to stimulate a robust immune response against HPV antigens to prevent infections that can lead to cervical cancer and other HPV-related conditions. It is currently in the discovery and preclinical stages of development.

Targets

HPV16 E7 (Human papillomavirus 16 E7 protein)

Beyond the preview

Go deeper on BTX-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTX-401.

Explore the full profile